title: Preclinical studies on tumor-specific fluorescent targeting agents: the need for a gold standard of tumor localization.
authors: Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands, s.keereweer@erasmusmc.nl.
authors: Stijn
authors: S
authors: Keereweer
authors: Pieter B A A
authors: PB
authors: Van Driel
authors: Clemens W G M
authors: CW
authors: Lowik
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized / Q000493:pharmacokinetics*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000378:metabolism*; D006801:Humans; D061848:Optical Imaging / Q000379:methods*; D019265:Spectroscopy, Near-Infrared / Q000379:methods*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized
references: Int J Cancer. 2012 Oct 1;131(7):1633-40
references: 22234729
references: Mol Imaging Biol. 2013 Oct;15(5):560-8
references: 23619897
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: Ann Surg Oncol. 2012 Nov;19(12):3879-87
references: 22669455
references: Clin Cancer Res. 2013 Jul 15;19(14):3745-54
references: 23674494
references: Nat Rev Cancer. 2012 Apr 19;12(5):323-34
references: 22513401
references: Mol Imaging Biol. 2013 Dec;15(6):722-9
references: 23715932
references: Cancer Res. 2003 Apr 15;63(8):1727-30
references: 12702551